Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Cash & Equivalents (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash & Equivalents for 15 consecutive years, with $20.2 million as the latest value for Q1 2026.

  • Quarterly Cash & Equivalents rose 23.08% to $20.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $20.2 million through Jan 2026, up 23.08% year-over-year, with the annual reading at $15.2 million for FY2025, 69.76% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $20.2 million at PharmaCyte Biotech, up from $15.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $86.6 million in Q1 2022, with the low at $13.2 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $50.9 million, with a median of $61.2 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents skyrocketed 8471.89% in 2022, then plummeted 73.23% in 2025.
  • Over 5 years, Cash & Equivalents stood at $77.0 million in 2022, then dropped by 4.6% to $73.4 million in 2023, then crashed by 71.62% to $20.8 million in 2024, then dropped by 26.07% to $15.4 million in 2025, then skyrocketed by 30.89% to $20.2 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $20.2 million, $15.4 million, and $13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.